Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Background: MICA and MICB are tightly regulated stress-induced proteins that trigger the immune system by binding to the activating receptor NKG2D on cytotoxic lymphocytes. MICA and MICB are highly polymorphic molecules with prevalent expression on several types of solid tumors and limited expression in normal/healthy tissues, making them attractive targets for therapeutic intervention. Methods: We have generated a series of anti-MICA and MICB cross-reactive antibodies with the unique feature of binding to the most prevalent isoforms of both these molecules. Results: The anti-MICA and MICB antibody MICAB1, a human IgG1 Fc-engineered monoclonal antibody (mAb), displayed potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) of MICA/B-expressing tumor cells in vitro . However, it showed insufficient efficiency against solid tumors in vivo , which prompted the development of antibody-drug conjugates (ADC). Indeed, optimal tumor control was achieved with MICAB1-ADC format in several solid tumor models, including patient-derived xenografts (PDX) and carcinogen-induced tumors in immunocompetent MICAgen transgenic mice. Conclusions: These data indicate that MICA and MICB are promising targets for cytotoxic immunotherapy.
Competing Interests: Competing interests: M.M-K., A.M., D.B., C.B., L.G., B.R., R.R., C.P., S.C., N.A., N.V., S.T., A.J-G., G.G., Y.M., I.P., E.V are employees of Innate Pharma. A.S. had research contracts with Innate Pharma, and PDI Therapeutics, as well as consulting and stock ownership of PDI Therapeutics. The other authors have no competing financial interests to declare.
(Copyright: © 2021 Bléry M et al.)